UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacological characterization of JNJ-28583867, a histamine H3 receptor antagonist and serotonin reuptake inhibitor

European journal of pharmacology, 2007-12, Vol.576 (1-3), p.43-54

2007

Volltextzugriff (PDF)

Behavioral Characterization of Mice Lacking Histamine H3 Receptors

Molecular pharmacology, 2002-08, Vol.62 (2), p.389

2002

Volltextzugriff (PDF)

Patient Voice in Rare Disease Drug Development and Endpoints

Therapeutic innovation & regulatory science, 2017-03, Vol.51 (2), p.257-263

2017

Volltextzugriff (PDF)

Pyrrolidino-tetrahydroisoquinolines as potent dual H3 antagonist and serotonin transporter inhibitors

Bioorganic & medicinal chemistry letters, 2007-05, Vol.17 (9), p.2603-2607

2007

Volltextzugriff (PDF)

Novel Benzamide-Based Histamine H3 Receptor Antagonists: The Identification of Two Candidates for Clinical Development

ACS medicinal chemistry letters, 2015-04, Vol.6 (4), p.450-454

2015

Volltextzugriff (PDF)

Benzylamine histamine H3 antagonists and serotonin reuptake inhibitors

Bioorganic & medicinal chemistry letters, 2007-09, Vol.17 (17), p.4799-4803

2007

Volltextzugriff (PDF)

Population Pharmacokinetics and Pharmacodynamics of AG-519, a Pyruvate Kinase Activator for the Treatment of Pyruvate Kinase Deficiency, in Human Healthy Volunteers

Blood, 2016-12, Vol.128 (22), p.1263-1263

2016

Volltextzugriff (PDF)

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of AG-519, an Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects

Blood, 2016-12, Vol.128 (22), p.1264-1264

2016

Volltextzugriff (PDF)

Characterization of Metabolic Response to AG-348, an Allosteric Activator of Red Cell Pyruvate Kinase, in Healthy Volunteers and Pyruvate Kinase Deficiency Patients

Blood, 2016-12, Vol.128 (22), p.2452-2452

2016

Volltextzugriff (PDF)

Immunogenicity of idursulfase and clinical outcomes in very young patients

Orphanet journal of rare diseases, 2015-04, Vol.10

2015

Volltextzugriff (PDF)

Identification of an Intramolecular Interaction between Small Regions in Type V Adenylyl Cyclase that Influences Stimulation of Enzyme Activity by Gsα

Proceedings of the National Academy of Sciences - PNAS, 1997-09, Vol.94 (18), p.9602-9607

1997

Volltextzugriff (PDF)

Behavioral Characterization of Mice Lacking Histamine H 3 Receptors

Molecular pharmacology, 2002-08, Vol.62 (2), p.389-397

2002

Volltextzugriff (PDF)

Lead identification of acetylcholinesterase inhibitors–histamine H 3 receptor antagonists from molecular modeling

Bioorganic & medicinal chemistry, 2008-03, Vol.16 (6), p.2968-2973

2008

Volltextzugriff (PDF)

Antibody response to investigational intrathecal enzyme replacement therapy with idursulfase-IT in pediatric Hunter syndrome patients with cognitive impairment

Molecular genetics and metabolism, 2015-02, Vol.114 (2), p.S53-S53

2015

Volltextzugriff (PDF)

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Encenicline, a Selective [alpha]7Nicotinic Receptor Partial Agonist, in Single Ascending-dose and Bioavailability Studies

Clinical therapeutics, 2015-02, Vol.37 (2), p.311

2015

Volltextzugriff (PDF)

A New Class of Diamine-Based Human Histamine H 3 Receptor Antagonists: 4-(Aminoalkoxy)benzylamines

Journal of medicinal chemistry, 2003-08, Vol.46 (18), p.3938-3944

2003

Volltextzugriff (PDF)

Development of a prototype reporter-based assay for the evaluation of gap junctional intercellular communication

Biotechnology letters, 2001-10, Vol.23 (19), p.1559-1563

2001

Volltextzugriff (PDF)

Long-term biomarker and cognitive follow-up of children with Hunter syndrome receiving intrathecal enzyme replacement therapy

Molecular genetics and metabolism, 2015-02, Vol.114 (2), p.S83-S83

2015

Volltextzugriff (PDF)

Limited clinical impact of anti-idursulfase antibodies developed during long-term idursulfase enzyme replacement therapy (ERT) in mucopolysaccharidosis II (MPS II, Hunter syndrome) patients aged 5-35 years

Molecular genetics and metabolism, 2014-02, Vol.111 (2), p.S53-S53

2014

Volltextzugriff (PDF)

Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment

Molecular genetics and metabolism, 2014-02, Vol.111 (2), p.S54-S54

2014

Volltextzugriff (PDF)

Pharmacological characterization of JNJ-28583867, a histamine H 3 receptor antagonist and serotonin reuptake inhibitor

European journal of pharmacology, 2007-12, Vol.576 (1), p.43-54

2007

Volltextzugriff (PDF)

4-Phenoxypiperidines: Potent, Conformationally Restricted, Non-Imidazole Histamine H 3 Antagonists

Journal of medicinal chemistry, 2005-03, Vol.48 (6), p.2229-2238

2005

Volltextzugriff (PDF)

Investigational intrathecal (IT) enzyme replacement therapy for the severe form of Hunter syndrome (mucopolysaccharidosis type II, MPS II)

Molecular genetics and metabolism, 2014-02, Vol.111 (2), p.S79-S79

2014

Volltextzugriff (PDF)

Heterocyclic replacement of the central phenyl core of diamine-based histamine H 3 receptor antagonists

European journal of medicinal chemistry, 2009-11, Vol.44 (11), p.4413-4425

2009

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

KollektionMEDLINE

Zeitschrift / SerieCheminform

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Englisch
(55)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacological characterization of JNJ-28583867, a histamine H3 receptor antagonist and serotonin reuptake inhibitor

Behavioral Characterization of Mice Lacking Histamine H3 Receptors

Patient Voice in Rare Disease Drug Development and Endpoints

Pyrrolidino-tetrahydroisoquinolines as potent dual H3 antagonist and serotonin transporter inhibitors

Novel Benzamide-Based Histamine H3 Receptor Antagonists: The Identification of Two Candidates for Clinical Development

Benzylamine histamine H3 antagonists and serotonin reuptake inhibitors

Population Pharmacokinetics and Pharmacodynamics of AG-519, a Pyruvate Kinase Activator for the Treatment of Pyruvate Kinase Deficiency, in Human Healthy Volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of AG-519, an Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects

Characterization of Metabolic Response to AG-348, an Allosteric Activator of Red Cell Pyruvate Kinase, in Healthy Volunteers and Pyruvate Kinase Deficiency Patients

Immunogenicity of idursulfase and clinical outcomes in very young patients

Identification of an Intramolecular Interaction between Small Regions in Type V Adenylyl Cyclase that Influences Stimulation of Enzyme Activity by Gsα

Behavioral Characterization of Mice Lacking Histamine H 3 Receptors

Lead identification of acetylcholinesterase inhibitors–histamine H 3 receptor antagonists from molecular modeling

Antibody response to investigational intrathecal enzyme replacement therapy with idursulfase-IT in pediatric Hunter syndrome patients with cognitive impairment

Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Encenicline, a Selective [alpha]7Nicotinic Receptor Partial Agonist, in Single Ascending-dose and Bioavailability Studies

A New Class of Diamine-Based Human Histamine H 3 Receptor Antagonists: 4-(Aminoalkoxy)benzylamines

Development of a prototype reporter-based assay for the evaluation of gap junctional intercellular communication

Long-term biomarker and cognitive follow-up of children with Hunter syndrome receiving intrathecal enzyme replacement therapy

Limited clinical impact of anti-idursulfase antibodies developed during long-term idursulfase enzyme replacement therapy (ERT) in mucopolysaccharidosis II (MPS II, Hunter syndrome) patients aged 5-35 years

Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment

Pharmacological characterization of JNJ-28583867, a histamine H 3 receptor antagonist and serotonin reuptake inhibitor

4-Phenoxypiperidines: Potent, Conformationally Restricted, Non-Imidazole Histamine H 3 Antagonists

Investigational intrathecal (IT) enzyme replacement therapy for the severe form of Hunter syndrome (mucopolysaccharidosis type II, MPS II)

Heterocyclic replacement of the central phenyl core of diamine-based histamine H 3 receptor antagonists

Aktive Filter

Suchergebnisse filtern